medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2022, Number 3

<< Back Next >>

Medicina & Laboratorio 2022; 26 (3)

Clinical and cytogenetic characterization of a cohort of patients with acute promyelocytic leukemia treated at a University Hospital in Medellín, Colombia Leonardo

Mejía-Buriticá L, Ocampo-Medina M, Ospina-Ospina S, Regino-Agamez CA, Vásquez-Palacio G, Torres-Hernández JD

Language: Spanish
References: 45
Page: 273-286
PDF size: 99.82 Kb.


ABSTRACT

Introduction. Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML), characterized by a particularly aggressive clinical behavior, that in the absence of treatment is usually fatal. The objective of this work was to determine the clinical and cytogenetic characteristics of a cohort of patients with APL, in order to evaluate their relationship with the outcome and prognosis of these patients. Methodology. An observational, descriptive, retrospective study of patients older than 15 years with a diagnosis of APL treated at the Hospital Universitario San Vicente Fundación, between 2012 and 2020, was carried out. Results. A total of 32 patients were included. The mean age at diagnosis was 37 years, 84.4% of the patients had the t(15;17) in the karyotype, and 93.75% had positive FISH. 12.5% of cases had a complex karyotype. Mortality in the first 30 days was 15.6%, with bleeding being the most common cause of death. All patients who survived achieved complete remission (84.3%). In an average follow-up of 24 months, 14.8% of cases relapsed. In the bivariate analysis, a relationship was found between the male sex and having a complex karyotype (p‹0.015). No relationship was found between complex karyotype and early mortality (p=0.358), nor between complex karyotype and relapse (p=0.052). Conclusions. We present the clinical and cytogenetic characteristics of a cohort of patients with APL in Colombia. Central nervous system bleeding was the main cause of early mortality, with all surviving patients achieving complete remission on induction therapy. Mortality, complete remission and relapse rates were similar to those reported by other Latin American series, but lower than studies from European countries. Contrary to what has been reported in other studies, no relationship was found between complex karyotype and early mortality or relapse.


REFERENCES

  1. Ryan MM. Acute promyelocytic leukemia: Asummary. J Adv Pract Oncol 2018;9:178-187.

  2. Lo-Coco F, Avvisati G, Vignetti M, Thiede C,Orlando SM, Iacobelli S, et al. Retinoic acidand arsenic trioxide for acute promyelocyticleukemia. N Engl J Med 2013;369:111-121.https://doi.org/10.1056/NEJMoa1300874.

  3. Arber DA, Orazi A, Hasserjian R, Thiele J,Borowitz MJ, Le Beau MM, et al. The 2016revision to the World Health Organization classificationof myeloid neoplasms and acute leukemia.Blood 2016;127:2391-2405. https://doi.org/10.1182/blood-2016-03-643544.

  4. Rashidi A, Silverberg ML, Conkling PR, FisherSI. Thrombosis in acute promyelocytic leukemia.Thromb Res 2013;131:281-289. https://doi.org/10.1016/j.thromres.2012.11.024.

  5. Xiao M, Zhou P, Liu Y, Wei S, Li D, Li W,et al. Predictive factors for differentiatingthrombohemorrhagic disorders in high-riskacute promyelocytic leukemia. Thromb Res2022;210:33-41. https://doi.org/10.1016/j.thromres.2021.12.020.

  6. Hambley BC, Tomuleasa C, Ghiaur G. Coagulopathyin acute promyelocytic leukemia:Can we go beyond supportive care? FrontMed (Lausanne) 2021;8:722614. https://doi.org/10.3389/fmed.2021.722614.

  7. Kirtane K, Lee SJ. Racial and ethnic disparitiesin hematologic malignancies. Blood2017;130:1699-1705. https://doi.org/10.1182/blood-2017-04-778225.

  8. Thomas X. Acute promyelocytic leukemia:A history over 60 years-from the most malignantto the most curable form of acute leukemia.Oncol Ther 2019;7:33-65. https://doi.org/10.1007/s40487-018-0091-5.

  9. Sant M, Allemani C, Tereanu C, De AngelisR, Capocaccia R, Visser O, et al. Incidence ofhematologic malignancies in Europe by morphologicsubtype: results of the HAEMACAREproject. Blood 2010;116:3724-3734. https://doi.org/10.1182/blood-2010-05-282632.

  10. Rego EM, Jácomo RH. Epidemiology andtreatment of acute promyelocytic leukemia inlatin america. Mediterr J Hematol Infect Dis2011;3:e2011049. https://doi.org/10.4084/mjhid.2011.049.

  11. Milanés-Roldán MT, Hernández-Ramírez P,Svarch-Guerchicoff E, Martínez-Antuña G,Ballester-Santovenia JM. Frecuencia de laleucemia promielocítica en Cuba. Rev CubanaHematol Inmunol Hemoter 2001;17:49-54.

  12. Jácomo RH, Melo RA, Souto FR, de MattosER, de Oliveira CT, Fagundes EM, et al. Clinicalfeatures and outcomes of 134 Brazilianswith acute promyelocytic leukemia who receivedATRA and anthracyclines. Haematologica2007;92:1431-1432. https://doi.org/10.3324/haematol.10874.

  13. De Salvo L, Weir-Medina J, Gómez-SánchezO, de Baena ES, de Ramos BU, Guevara J, etal. [Acute promyelocytic leukemia in the westof Venezuela]. Sangre (Barc) 1989;34:329-331.

  14. Ruiz-Argüelles GJ. Promyelocytic leukemia inMexican mestizos. Blood 1997;89:348-349.

  15. Rego EM, Kim HT, Ruiz-Argüelles GJ, UndurragaMS, Uriarte Mdel R, Jacomo RH, et al.Improving acute promyelocytic leukemia (APL)outcome in developing countries through networking,results of the International Consortiumon APL. Blood 2013;121:1935-1943. https://doi.org/10.1182/blood-2012-08-449918.

  16. Martínez O. Epidemiología de la leucemiapromielocítica aguda en el adulto. Acta MedColomb 2004;29:108-111.

  17. Martínez-Cordero H, Ospina-Idarraga J, Castañeda-Contreras X, Rico-Mendoza A, IdroboH, Martinez-Correa L, et al. Acute promyelocyticleukemia (apl): Seasonal behavior inColombia for the period 2009-2019. Blood2020;136:38-39. https://doi.org/10.1182/blood-2020-143191.

  18. Pardo-Gonzalez CA, Lagos-Ibarra JJ, Linares-Ballesteros A, Sarmiento-Urbina IC, Contreras-Acosta AD, Cabrera-Bernal EV, et al. Resultsof the implementation of the PETHEMALPA 99 protocol for treating children with acutepromyelocytic leukemia in Bogotá, Colombia.Rev Fac Med 2021;69.

  19. Ravandi F. Therapy-related acute promyelocyticleukemia. Haematologica 2011;96:493-495.https://doi.org/10.3324/haematol.2011.041970.

  20. Rashidi A, Fisher SI. Therapy-related acutepromyelocytic leukemia: a systematic review.Med Oncol 2013;30:625. https://doi.org/10.1007/s12032-013-0625-5.

  21. Beaumont M, Sanz M, Carli PM, MaloiselF, Thomas X, Detourmignies L, et al. Therapy-related acute promyelocytic leukemia. JClin Oncol 2003;21:2123-2137. https://doi.org/10.1200/jco.2003.09.072.

  22. Park JH, Qiao B, Panageas KS, SchymuraMJ, Jurcic JG, Rosenblat TL, et al. Early deathrate in acute promyelocytic leukemia remainshigh despite all-trans retinoic acid. Blood2011;118:1248-1254. https://doi.org/10.1182/blood-2011-04-346437.

  23. Lehmann S, Deneberg S, Antunovic P, Rangert-Derolf Å, Garelius H, Lazarevic V, et al.Early death rates remain high in high-risk APL:update from the Swedish Acute Leukemia Registry1997-2013. Leukemia 2017;31:1457-1459. https://doi.org/10.1038/leu.2017.71.

  24. Xu F, Wang C, Yin C, Jiang X, Jiang L, WangZ, et al. Analysis of early death in newly diagnosedacute promyelocytic leukemia patients.Medicine (Baltimore) 2017;96:e9324. https://doi.org/10.1097/md.0000000000009324.

  25. Naymagon L, Mascarenhas J. Hemorrhage inacute promyelocytic leukemia: Can it be predictedand prevented? Leuk Res 2020;94:106356.https://doi.org/10.1016/j.leukres.2020.106356.

  26. De Stefano V, Sorà F, Rossi E, Chiusolo P, LaurentiL, Fianchi L, et al. The risk of thrombosisin patients with acute leukemia: occurrence ofthrombosis at diagnosis and during treatment.J Thromb Haemost 2005;3:1985-1992. https://doi.org/10.1111/j.1538-7836.2005.01467.x.

  27. Flowers CR, Seidenfeld J, Bow EJ, KartenC, Gleason C, Hawley DK, et al. Antimicrobialprophylaxis and outpatient managementof fever and neutropenia in adults treated formalignancy: American Society of Clinical Oncologyclinical practice guideline. J Clin Oncol2013;31:794-810. https://doi.org/10.1200/jco.2012.45.8661.

  28. Yadegarynia D, Tarrand J, Raad I, Rolston K.Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003;37:1144-1145. https://doi.org/10.1086/378305.

  29. Kuderer NM, Dale DC, Crawford J, Cosler LE,Lyman GH. Mortality, morbidity, and cost associatedwith febrile neutropenia in adult cancerpatients. Cancer 2006;106:2258-2266. https://doi.org/10.1002/cncr.21847.

  30. Bewersdorf JP, Zeidan AM. Hyperleukocytosisand leukostasis in acute myeloid leukemia:Can a better understanding of the underlyingmolecular pathophysiology lead to noveltreatments? Cells 2020;9:2310. https://doi.org/10.3390/cells9102310.

  31. Sanz MA, Fenaux P, Tallman MS, Estey EH,Löwenberg B, Naoe T, et al. Management ofacute promyelocytic leukemia: updated recommendationsfrom an expert panel of the EuropeanLeukemiaNet. Blood 2019;133:1630-1643.https://doi.org/10.1182/blood-2019-01-894980.

  32. Coutre S. Classification and risk stratification foracute promyelocytic leukemia. Clin LymphomaMyeloma Leuk 2010;10:S127-129. https://doi.org/10.3816/CLML.2010.s.024.

  33. Mejía-Buriticá L, Torres-Hernández JD, VásquezGdJ. Leucemia promielocítica aguda. Estadodel arte. Iatreia 2021;34:42-53.

  34. Mrózek K, Eisfeld AK, Kohlschmidt J, CarrollAJ, Walker CJ, Nicolet D, et al. Complex karyotypein de novo acute myeloid leukemia: typicaland atypical subtypes differ molecularlyand clinically. Leukemia 2019;33:1620-1634.https://doi.org/10.1038/s41375-019-0390-3.

  35. Labrador J, Luño E, Vellenga E, Brunet S,González-Campos J, Chillón MC, et al. Clinicalsignificance of complex karyotype atdiagnosis in pediatric and adult patients withde novo acute promyelocytic leukemia treatedwith ATRA and chemotherapy. Leuk Lymphoma2019;60:1146-1155. https://doi.org/10.1080/10428194.2018.1522438.

  36. Lou Y, Suo S, Tong H, Ye X, Wang Y, Chen Z,et al. Characteristics and prognosis analysis ofadditional chromosome abnormalities in newlydiagnosed acute promyelocytic leukemia treatedwith arsenic trioxide as the front-line therapy.Leuk Res 2013;37:1451-1456. https://doi.org/10.1016/j.leukres.2013.07.030.

  37. Poiré X, Moser BK, Gallagher RE, Laumann K,Bloomfield CD, Powell BL, et al. Arsenic trioxidein front-line therapy of acute promyelocyticleukemia (C9710): prognostic significance ofFLT3 mutations and complex karyotype. LeukLymphoma 2014;55:1523-1532. https://doi.org/10.3109/10428194.2013.842985.

  38. Epstein-Peterson ZD, Derkach A, Geyer S,Mrózek K, Kohlschmidt J, Park JH, et al. Effectof additional cytogenetic abnormalities on survivalin arsenic trioxide-treated acute promyelocyticleukemia. Blood Adv 2022. https://doi.org/10.1182/bloodadvances.2021006682.

  39. Lucena-Araujo AR, Kim HT, Jacomo RH,Melo RA, Bittencourt R, Pasquini R, et al.Internal tandem duplication of the FLT3 geneconfers poor overall survival in patients withacute promyelocytic leukemia treated with alltransretinoic acid and anthracycline-basedchemotherapy: an International Consortiumon Acute Promyelocytic Leukemia Study. AnnHematol 2014;93:2001-2010. https://doi.org/10.1007/s00277-014-2142-9.

  40. Picharski GL, Andrade DP, Fabro A, LenziL, Tonin FS, Ribeiro RC, et al. The impact ofFLT3 gene mutations in acute promyelocyticleukemia: A meta-analysis. Cancers (Basel)2019;11:1311. https://doi.org/10.3390/cancers11091311.

  41. Breccia M, Loglisci G, Loglisci MG, Ricci R,Diverio D, Latagliata R, et al. FLT3-ITD conferspoor prognosis in patients with acute promyelocyticleukemia treated with AIDA protocols:long-term follow-up analysis. Haematologica2013;98:e161-163. https://doi.org/10.3324/haematol.2013.095380.

  42. Tripon F, Crauciuc GA, Bogliş A, MoldovanV, Sándor-Kéri J, Benedek IJ, et al. Co-occurrenceof PML-RARA gene fusion, chromosome8 trisomy, and FLT3 ITD mutation in a youngfemale patient with de novo acute myeloidleukemia and early death: A CARE case report.Medicine (Baltimore) 2020;99:e19730. https://doi.org/10.1097/md.0000000000019730.

  43. Rasekh EO, Elsayed GM, Madney Y, ElGammal MM. Prognostic significance ofbcr-1 and bcr-3 isoforms of PML-RARA andFLT3-ITD in patients with acute promyelocyticleukemia. Clin Lymphoma Myeloma Leuk2020;20:156-167. https://doi.org/10.1016/j.clml.2019.08.006.

  44. Stahl M, Tallman MS. Differentiation syndromein acute promyelocytic leukaemia. BrJ Haematol 2019;187:157-162. https://doi.org/10.1111/bjh.16151.

  45. Sanz MA, Montesinos P, Kim HT, Ruiz-ArgüellesGJ, Undurraga MS, Uriarte MR, etal. All-trans retinoic acid with daunorubicin oridarubicin for risk-adapted treatment of acutepromyelocytic leukaemia: a matched-pairanalysis of the PETHEMA LPA-2005 and ICAPLstudies. Ann Hematol 2015;94:1347-1356.https://doi.org/10.1007/s00277-015-2393-0.




2020     |     www.medigraphic.com